Stay updated on Nivolumab Post-chemoradiotherapy Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Post-chemoradiotherapy Clinical Trial page.

Latest updates to the Nivolumab Post-chemoradiotherapy Clinical Trial page
- Check2 days agoChange DetectedA new revision tag Revision: v3.6.0 was added, and a large set of terms related to drugs, diseases, and other study metadata were removed, altering how the study is described and indexed on the ClinicalTrials.gov record.SummaryDifference19%

- Check10 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a small update to the page's versioning/documentation rather than a substantive edit to study details or visible content.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedDifference0.1%

- Check53 days agoChange DetectedThe page has been updated to a newer ClinicalTrials.gov revision version (v3.5.3 instead of v3.5.2), reflecting a site update rather than any change to the underlying study information.SummaryDifference0.1%

- Check60 days agoChange DetectedOno Pharmaceutical Co., Ltd. is added as a collaborator with the standardized company name. The page revision is updated to v3.5.2, replacing the previous Ono Pharmaceutical Co. Ltd and revision v3.5.0.SummaryDifference0.1%

- Check89 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Post-chemoradiotherapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Post-chemoradiotherapy Clinical Trial page.